CD30+ Cancer Detection and Treatment Methods Patent

USPTO granted US Patent No. US12590968B2 to Seagen Inc. on March 31, 2026. The patent covers methods for diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers, with 4 claims in CPC classes including C07K 16/2878 (immunoglobulins) and A61K 47/6849 (conjugates for therapeutic delivery). The original application was filed as No. 17747591 on May 18, 2022.

Pharmaceutical companies and biotechnology firms developing CD30-targeted oncology therapies should review this patent for potential freedom-to-operate implications. IP counsel should assess whether existing or planned research programs may fall within the granted claim scope. Parties interested in licensing or design-around strategies should obtain and review the full patent document to understand the precise boundaries of the 4 granted claims.